Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

Drug firm Pfizer on Monday, July 29 reported a 61.2% year-on-year jump in net profit to Rs 150.7 crore for the first quarter ended June 2024 against Rs 94 crore it posted in the corresponding quarter of the previous fiscal.

Key Takeaways from Pfizer’s Financial Performance

• Pfizer reported a 61.2% YoY jump in net profit to Rs 150.7 crore for the first quarter ended June 2024.
• The company’s sales rose 5.9% to Rs 563 crore compared to Rs 531.4 crore in the corresponding period of the preceding fiscal.
• EBITDA jumped 60.2% to Rs 177.5 crore in June 2024 over Rs 110.7 crore in the corresponding period in the previous fiscal.
• EBITDA margin stood at 31.5% in the reporting quarter compared to 20.9% in the corresponding period in the previous fiscal. 

The company's revenue from operations rose 5.9% to Rs 563 crore compared to Rs 531.4 crore in the corresponding period of the preceding fiscal.

At the operating level, EBITDA jumped 60.3% to Rs 177.5 crore in the first quarter of this fiscal over Rs 110.7 crore in the corresponding period in the previous fiscal.

EBITDA (earnings before interest, tax, depreciation, and amortisation) margin stood at 31.5% in the reporting quarter as compared to 20.9% in the corresponding period in the previous fiscal. 

About Pfizer Limited

Pfizer Limited, an American multinational firm founded in 1849, is one of the world's largest pharmaceutical corporations. The organisation is notable for developing and manufacturing vaccinations for many industries. These include immunology, cardiology, cancer, neurology, and endocrinology. The company's significant products include Lipitor, Lyrica, Diflucan, Zithromax, Viagra, Celebrex, and Prevnar.

Internal medicine, rare illnesses, immunology, hospitals, vaccinations, inflammation, and cancer are among the several divisions that make up the Biopharma category. The business established a joint venture with the massive UK pharmaceutical corporation GlaxoSmithKline in December 2018. Through a number of mergers between 2000 and 2010, the corporation expanded. Warner-Lambert (2000), Wyeth (2009), and Pharmacia (2003) are a few of these. In 2015, the business made another effort to combine for $160 billion with Allergan. However, after Obama's government passed new legislation aimed at restricting corporate tax inversions, the business called off the transaction in April 2016.

Pfizer operates 90 locations in 59 different nations. The US, Canada, France, UK, Germany, Italy, Sweden, Spain, Switzerland, Netherlands, Belgium, Australia, Israel, Argentina, India, Belarus, Austria, Brazil, Chile, Bulgaria, China, and so on are some of these. In the 2020 list of America's Best Employers for New Grads, the firm came in at number nine. 2020's Global 2000 list saw Pfizer secure the 49th spot. In 2018 America's Largest Public Companies, it was rated fifteenth as well. Additionally, the business was named 15th in Canada's Best Employers 2020. In 2020, it was placed 64th out of 500 firms on the Fortune 500 list. The New York Stock Exchange (NYSE) is where Pfizer shares are traded, and its ticker is "PFE."

Read More About Pfizer Share Price Here!